Leveraging synthetic peptide nucleic acids (PNAs) to bind RNA with unusually high affinity to create, American researchers have created gRNA spacer-targeted, or ‘antispacer’, PNAs as a tool to modulate Cas9 binding and activity in cells. The authors also show that short PAM-proximal antispacer PNAs achieve potent cleavage inhibition (over 2000-fold reduction) and that PAM-distal PNAs modify gRNA affinity to promote on-target specificity.
American researchers have studied the off-target effects of various CRISPR-Cas13 effectors. They find that the off-target effects of RxCas13d, a commonly used Cas13 effector, can be as strong as the level of on-target RNA knockdown. This might limit their utility in eukaryotic cells and highlights the need for caution when designing and interpreting Cas13-based knockdown experiments.
SNIPR BIOME has opened a new BSL2/GMO2-classified laboratory in Copenhagen, Denmark, among the largest of its kind in Scandinavia and Northern Europe. It will handle clinical samples from the phase 1 clinical trial with SNIPR001 and expand its CRISPR and microbiome portfolio. SNIPR BIOME uses proprietary CRISPR technologies to selectively target microbial pathogens and remodel the microbiome to address critical unmet medical needs.
Sherlock Biosciences has raised $80 million in a Series B financing led by Novalis LifeSciences and new investors Illumina Ventures, Albany Capital and Catalio Capital Management. This new funding will drive the development of products and partnerships, enabled by the company's CRISPR-based platform for the decentralised diagnostic platform for DNA and RNA detection.
On the upside for Intellia Therapeutics, the FDA has granted the company orphan drug designation for its ex vivo investigational T cell receptor (TCR)-T cell therapy, NTLA-5001, to treat acute myeloid leukaemia (AML). NTLA-5001 is an autologous TCR-T cell therapy designed to target the Wilms' Tumor (WT1) antigen, which is highly expressed in AML and many other hematologic and solid tumours.
A review by Spanish researchers takes a closer look at mRNA and gene editing late-breaking therapies in liver diseases. They discuss the potential of CRISPR Cas9-based technologies in vivo modification of the cellular genome with therapeutic purposes using gene supplementation, correction, or silencing. The review summarises the different gene-editing strategies applied to treating liver diseases, highlighting their therapeutic efficacy and safety concerns.
A mini-review by Indian researchers discuss the emerging therapeutic approach using CRISPR-dCas9 to target head and neck cancer epigenetics. The authors suggest that with technological advancements and successful attempts, epigenome editing by CRISPR-dCas9 will have vast therapeutic applications and be widely employed in the near future.
Wednesday, we reported that the first patient had been dosed in a CRISPR trial for acute myeloid leukaemia. Intellia Therapeutics recently announced that the first patient had been dosed in its Phase 1/2a CRISPR trial for acute myeloid leukaemia (AML). The new therapeutic candidate, NTLA-5001, is a CRISPR-edited T cell receptor therapy designed to target Wilm's Tumour (WT1) antigen, found on AML and several other blood cancers of certain types of solid cancer.
This Monday's feature was about finding the secret ingredient for CRISPR-Cas3 editing in human cells. For years, Dr Yan Zhang at the University of Michigan wondered why scientists struggled to adapt certain type I CRISPR systems for gene editing in human cells. Then her lab discovered a hidden Cas protein, Cas11, which turns out to be critical for the function of many type I CRISPR systems.
The efforts of Ben Lamm and George Church to recreate the woolly mammoth by CRISPR-engineering the genes of Asian elephants have got a helping hand from an additional $60 million in funding. However, a new study by Danish evolutionary biologists suggests that the efforts at best will result in a hairy Asian elephant adapted to live in the cold. The study managed to recover about 95% of the genome of an extinct relative to the Norway brown rat but missed some genes believed to be essential to smell and the immune system. The authors conclude that even a few missing genes in animals' re-created genomes could be problematic.
To get more of the CRISPR Medicine News delivered to your inbox, sign up to the free weekly CMN Newsletter here.